Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study

Supportive Care in Cancer

Volumn 24, Issue 2, 2016, Pages 597-603

  Brito, M ^a   Esteves, S ^a   Andre R ^a,b   Isidoro, M ^a   Moreira, A ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b Oncology Department   (Portugal)

Author keywords

Breast cancer; Febrile neutropenia; Filgrastim; G CSF biosimilar

Indexed keywords

BIOSIMILAR AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FILGRASTIM; PEGFILGRASTIM; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; TAXOID;

ABSOLUTE NEUTROPHIL COUNT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; DRUG DOSE REDUCTION; DRUG UTILIZATION; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; SEPTIC SHOCK; THERAPY DELAY; URINARY TRACT INFECTION; BREAST NEOPLASMS; CHEMICALLY INDUCED; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOSIMILAR PHARMACEUTICALS; BREAST NEOPLASMS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEBRILE NEUTROPENIA; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84952871952     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2818-2     Document Type: Article

References (26)

1. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266
2. Courtney DM, Aldeen AZ, Gorman SM et al (2007) Cancer associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist 12:1019–1026
3. Elting LS, Lu C, Escalante CP, Giordano SH et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611
4. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15
5. Chirivella I, Bermejo B, Insa A et al (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114:479–484
6. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313
7. Martín M, Seguí MA, Antón A et al (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363:2200–2210
8. Von Minckwitz G, Kümmel S, du Bois A et al (2008) Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19:292–298
9. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32
10. Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21:248–251
11. Crawford J, Armitage J, Balducci L et al (2013) Myeloid growth factors. National Comprehensive Cancer Network. J Natl Compr Cancer Netw 11:1266–1290
12. Rajan SS, Carpenter WR, Stearns SC, Lyman GH (2013) Short-term costs associated with primary prophylactic G-CSF use during chemotherapy. Am J Manag Care 19:150–159
13. Waller CF, Semiglazov VF, Tjulandin S et al (2010) A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 33:504–511
14. Passos-Coelho JL, Esteves S, Viera PA et al (2011) Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer–incidence of neutropenic fever outside clinical trials. Breast J 17:539–541
15. Hryniuk WM (1988) The importance of dose intensity in the outcome of chemotherapy. In: DeVita VT, Hellman S, Rosenburg SA (eds) Important advances in oncology. JB Lippincott, Philadelphia, pp 121–141
16. Product Monograph Neupogen: https://www.amgen.ca/Neupogen_PM.pdf
17. Holmes FA, Jones SE, O’Shaughnessy J et al (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903–909
18. Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35
19. EMA Nivestim™ assessment report: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001142/WC500093664.pdf
20. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431
21. González-Barca E, Fernández-Sevilla A, Carratalá J et al (1999) Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis 18:539–544
22. Hosmer W, Malin J, Wong M (2011) Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 19:333–341
23. Dranitsaris G, Rayson D, Vincent M et al (2008) Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol 31:369–374
24. Flowers CR, Seidenfeld J, Bow EJ et al (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794–810
25. Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 23:7974–7984
26. Kamioner D, Fruehauf S, Maloisel F et al (2013) Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. BMC Cancer 13:547